Skip to content
To the full analysis

Thermo Fisher Scientific stock: balance sheet and debt

TMO
$699.44Closing price of 12 Nov 2026MEQIRI Score 68 out of 100

Thermo Fisher Scientific has a debt to equity ratio of 0.74 and an interest coverage of 6.1x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.74
Interest coverage
6.1x
Current ratio
1.89
Cash & equivalents
$10.11B
Total assets
$110.34B
Equity ratio
48.5%
Goodwill
$49.36B
Plus intangible assets of $15.84B
Net debt
$29.28B

Total assets and equity ratio

How large the balance sheet of Thermo Fisher Scientific Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$21.26B$16.04B$8.52B65.4%$1.97B
2007$21.21B$15.87B$8.71B68.3%$1.56B
2008$21.09B$15.1B$8.68B70.8%$770.3M
2009$21.6B$15.32B$8.98B71.4%$612.2M
2010$21.39B$15.31B$9.27B71.8%$1.24B
2011$26.83B$19.8B$11.99B56.0%$6.01B
2012$27.44B$20.28B$12.47B56.3%$6.31B
2013$31.86B$19.57B$12.5B52.9%$4.66B
2014$42.85B$32.95B$18.84B48.0%$13.22B
2015$40.83B$31.59B$18.83B52.3%$12.02B
2016$45.91B$35.3B$21.33B46.9%$15.84B
2017$56.67B$41.97B$25.29B44.8%$19.67B
2018$56.23B$40.33B$25.35B49.1%$16.89B
2019$58.38B$39.73B$25.71B50.8%$16.09B
2020$69.05B$38.73B$26.04B50.0%$12.22B
2021$95.12B$62.07B$41.92B43.1%$31.86B
2022$97.15B$58.67B$41.2B45.4%$27.55B
2023$98.73B$60.69B$44.02B47.4%$28.34B
2024$97.32B$61.39B$45.85B51.0%$27.2B
2025$110.34B$65.2B$49.36B48.5%$29.28B

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$691.2M$13.91B$2.66B0.19
2007$639.2M$14.49B$2.2B0.15
2008$1.29B$14.93B$2.06B0.14
2009$1.57B$15.43B$2.18B0.14
2010$926M$15.36B$2.17B0.14
2011$1.02B$15.04B$7.03B0.47
2012$809.9M$15.46B$7.12B0.46
2013$5.83B$16.86B$10.49B0.62
2014$1.34B$20.55B$14.56B0.71
2015$452.1M$21.35B$12.47B0.58
2016$786M$21.54B$16.63B0.77
2017$1.34B$25.41B$21.01B0.83
2018$2.1B$27.59B$18.99B0.69
2019$2.4B$29.68B$18.49B0.62
2020$10.33B$34.51B$22.55B0.65
2021$4.48B$40.79B$36.34B0.89
2022$8.52B$43.98B$36.07B0.82
2023$8.08B$46.74B$36.42B0.78
2024$5.58B$49.58B$32.78B0.66
2025$10.11B$53.41B$39.39B0.74

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jan 2026)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy